Table 4 Antimicrobial susceptibility of major Gram-negative bacteria
Antibacterial | Major Gram-negative bacteria, N (%) of resistant strains | ||||
|---|---|---|---|---|---|
A. baumannii (n = 57) | K. Pneumoniae (n = 49) | S. Maltophilia (n = 10) | P.aeruginosa (n = 7) | E. coli (n = 8) | |
Ampicillin | – | 49 (100) | – | – | 7 (87.5) |
Ampicillin sulbactam | 53 (93.0) | 44 (89.8) | – | – | 2 (25.0) |
Piperacillin | 53 (93.0) | 43 (87.8) | – | 1 (14.3) | 7 (87.5) |
Piperacillin tazobactam | 52 (91.2) | 38 (77.6) | – | 1 (14.3) | 1 (12.5) |
Amoxicillin clavulanate | 57 (100) | 42 (85.7) | – | – | 1 (12.5) |
Cefazolin | – | 48 (98.0) | – | – | 7 (87.5) |
Cefuroxime | – | 43 (87.8) | – | – | 6 (75.0) |
Ceftriaxone | 52 (91.2) | 41 (83.7) | – | – | 6 (75.0) |
Ceftazidime | 52 (91.2) | 41 (83.7) | 9 (90.0) | 1 (14.3) | 3 (37.5) |
Cefoperazone sulbactam | 45 (78.9) | 39 (79.6) | – | – | – |
Cefepime | 53 (93.0) | 41 (83.7) | – | 1 (14.3) | 5 (62.5) |
Aztreonam | 57 (100) | 41 (83.7) | – | 2 (28.6) | 2 (25.0) |
Cefoxitin | – | 41 (83.7) | – | – | 0 (0) |
Meropenem | 52 (91.2) | 37 (75.5) | – | 3 (42.9) | 0 (0) |
Imipenem | 52 (91.2) | 37 (75.5) | – | 3 (42.9) | 0 (0) |
Amikacin | 48 (84.2) | 36 (73.5) | – | 0(0) | 0 (0) |
Gentamicin | 52 (91.2) | 39 (79.6) | – | 0(0) | 2 (25.0) |
Tobramycin | 50 (87.7) | 32 (65.3) | – | – | 2 (25.0) |
Levofloxacin | 52 (91.2) | 39 (79.6) | 3 (30.0) | 2 (28.6) | 6 (75.0) |
Ciprofloxacin | 52 (91.2) | 43 (87.8) | – | 2 (28.6) | 6 (75.0) |
Sulfamethoxazole trimethoprim | 48 (84.2) | 36 (73.5) | 0 (0) | – | 4 (50.0) |
Minocycline | 16 (28.1) | 23 (46.9) | 0 (0) | – | 2 (25.0) |
Tigecycline | 0 (0) | 1 (1.7) | – | – | 0 (0) |
ESBL | – | 43 (87.8) | – | – | 6 (75.0) |